Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $654 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $447 | $458 | $469 | $327 |
| Gross Profit | -$447 | -$458 | -$469 | $327 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $82,192 | $103,952 | $92,490 | $85,467 |
| G&A Expenses | $47,394 | $32,266 | $27,417 | $24,253 |
| SG&A Expenses | $47,394 | $32,266 | $27,417 | $24,253 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $147 | $147 | $147 | $147 |
| Operating Expenses | $129,586 | $136,218 | $119,907 | $109,720 |
| Operating Income | -$129,586 | -$136,218 | -$119,907 | -$109,066 |
| % Margin | – | – | – | -16,676.8% |
| Other Income/Exp. Net | $16,432 | $17,099 | $16,744 | $11,492 |
| Pre-Tax Income | -$113,154 | -$119,119 | -$103,163 | -$97,574 |
| Tax Expense | $670 | $0 | $0 | -$11,492 |
| Net Income | -$113,824 | -$119,119 | -$103,163 | -$86,082 |
| % Margin | – | – | – | -13,162.4% |
| EPS | -3.01 | -3.16 | -2.75 | -2.47 |
| % Growth | 4.7% | -14.9% | -11.3% | – |
| EPS Diluted | -3.01 | -3.16 | -2.75 | -2.47 |
| Weighted Avg Shares Out | 37,781 | 37,689 | 37,525 | 34,801 |
| Weighted Avg Shares Out Dil | 37,781 | 37,689 | 37,525 | 34,801 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,285 | $16,952 | $16,597 | $11,345 |
| Interest Expense | $11,492 | $0 | $0 | $0 |
| Depreciation & Amortization | $447 | $458 | $469 | $327 |
| EBITDA | -$101,215 | -$135,760 | -$119,438 | -$108,739 |
| % Margin | – | – | – | -16,626.8% |